Select Page

Study Drug: ABBV-154
Study Drug administration: IV and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease

Inclusion criteria: endoscopically and clinically active CD, failed biologics (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)

Exclusion criteria: current fistulizing disease, abscess, ostomy or ileoanal pouch, bowel resection within last 3 months, positive for C Difficile, Hepatitis B or C, HIV

Status: Upcoming